Completed PHASE2 INTERVENTIONAL 3-arm NCT04262856

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Sponsor: Arcus Biosciences, Inc.

Conditions Lung Cancer Non Small Cell Lung Cancer Nonsquamous Non Small Cell Lung Cancer Squamous Non Small Cell Lung Cancer

Interventions Domvanalimab Etrumadenant Zimberelimab

Updated 37 times since 2020 Last updated: Aug 25, 2025 Started: May 28, 2020 Primary completion: Jun 5, 2025 Completion: Jul 9, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer and Non Small Cell Lung Cancer and is currently completed. Arcus Biosciences, Inc. leads this study, which shows 37 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

37 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE2
Apr 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 32 earlier versions

Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Active Not Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Dec 2023 — Jun 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE2
Jun 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE2
Jan 2023 — May 2023 [monthly]

Active Not Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE2
May 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Feb 2022 — May 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Feb 2021 — May 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Sep 2020 — Dec 2020 [monthly]

Recruiting PHASE2
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE2
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE2
Jun 2020 — Jul 2020 [monthly]

Recruiting PHASE2
Mar 2020 — Jun 2020 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arcus Biosciences, Inc.
Gilead Sciences

Data source: Arcus Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albury, Australia , Birmingham, United States , Blacksburg, United States , Busan, South Korea , Cheongju-si, South Korea , Coffs Harbour, Australia , Elizabeth Vale, Australia , Englewood, United States , Fairfax, United States , Fort Worth, United States and 28 more locations